News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
278,251 Results
Type
Article (14920)
Company Profile (294)
Press Release (263032)
Multimedia
Podcasts (70)
Webinars (11)
Section
Business (80095)
Career Advice (159)
Deals (13346)
Drug Delivery (39)
Drug Development (50715)
Employer Resources (31)
FDA (5810)
Job Trends (5188)
News (145357)
Policy (10132)
Tag
Academia (991)
Accelerated approval (9)
Adcomms (14)
Allergies (70)
Alliances (21890)
ALS (99)
Alzheimer's disease (968)
Antibody-drug conjugate (ADC) (178)
Approvals (5896)
Artificial intelligence (201)
Autoimmune disease (69)
Automation (9)
Bankruptcy (105)
Best Places to Work (4584)
BIOSECURE Act (6)
Biosimilars (79)
Biotechnology (232)
Bladder cancer (86)
Brain cancer (34)
Breast cancer (268)
Cancer (2523)
Cardiovascular disease (196)
Career advice (144)
Career pathing (4)
CAR-T (176)
CDC (5)
Cell therapy (480)
Cervical cancer (11)
Clinical research (42742)
Collaboration (887)
Company closure (2)
Compensation (467)
Complete response letters (31)
COVID-19 (1101)
CRISPR (84)
C-suite (384)
Cystic fibrosis (101)
Data (3256)
Denatured (13)
Depression (67)
Diabetes (218)
Diagnostics (1376)
Digital health (9)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (138)
Drug pricing (41)
Drug shortages (3)
Duchenne muscular dystrophy (181)
Earnings (31148)
Editorial (21)
Employer branding (4)
Employer resources (29)
Events (50768)
Executive appointments (601)
FDA (7181)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (5)
Frontotemporal dementia (14)
Funding (801)
Gene editing (164)
Generative AI (16)
Gene therapy (413)
GLP-1 (460)
Government (1152)
Grass and pollen (3)
Guidances (161)
Healthcare (6641)
HIV (13)
Huntington's disease (35)
IgA nephropathy (55)
Immunology and inflammation (159)
Immuno-oncology (10)
Indications (37)
Infectious disease (1194)
Inflammatory bowel disease (143)
Inflation Reduction Act (10)
Influenza (33)
Intellectual property (132)
Interviews (19)
IPO (7358)
IRA (12)
Job creations (871)
Job search strategy (131)
Kidney cancer (9)
Labor market (18)
Layoffs (239)
Leadership (8)
Legal (1411)
Liver cancer (39)
Longevity (8)
Lung cancer (370)
Lymphoma (173)
Machine learning (18)
Management (7)
Manufacturing (287)
MASH (110)
Medical device (2650)
Medtech (2656)
Mergers & acquisitions (6502)
Metabolic disorders (601)
Multiple sclerosis (86)
NASH (14)
Neurodegenerative disease (149)
Neuropsychiatric disorders (47)
Neuroscience (1696)
NextGen: Class of 2025 (2047)
Non-profit (882)
Now hiring (28)
Obesity (267)
Opinion (117)
Ovarian cancer (111)
Pain (81)
Pancreatic cancer (116)
Parkinson's disease (182)
Partnered (11)
Patents (243)
Patient recruitment (224)
Peanut (40)
People (26408)
Pharmaceutical (47)
Pharmacy benefit managers (6)
Phase I (15115)
Phase II (19869)
Phase III (12565)
Pipeline (1746)
Policy (82)
Postmarket research (853)
Preclinical (6442)
Press Release (39)
Prostate cancer (119)
Psychedelics (47)
Radiopharmaceuticals (221)
Rare diseases (494)
Real estate (1443)
Recruiting (12)
Regulatory (9404)
Reports (19)
Research institute (1000)
Resumes & cover letters (18)
Rett syndrome (13)
RNA editing (15)
RSV (16)
Schizophrenia (106)
Series A (147)
Series B (105)
Service/supplier (1)
Sickle cell disease (68)
Special edition (17)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (2010)
State (1)
Stomach cancer (5)
Supply chain (29)
Tariffs (17)
The Weekly (56)
Vaccines (299)
Venture capital (44)
Weight loss (148)
Women's health (19)
Worklife (2)
Date
Today (47)
Last 7 days (444)
Last 30 days (1594)
Last 365 days (18246)
2025 (15119)
2024 (20664)
2023 (22543)
2022 (27000)
2021 (27999)
2020 (23521)
2019 (16382)
2018 (11834)
2017 (13871)
2016 (11918)
2015 (14391)
2014 (10416)
2013 (7490)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (58)
Alaska (3)
Arizona (62)
Arkansas (5)
Asia (17974)
Australia (3056)
California (5935)
Canada (1609)
China (607)
Colorado (208)
Connecticut (219)
Delaware (179)
Europe (38666)
Florida (738)
Georgia (182)
Hawaii (2)
Idaho (16)
Illinois (333)
India (25)
Indiana (136)
Iowa (10)
Japan (167)
Kansas (75)
Kentucky (7)
Louisiana (5)
Maine (11)
Maryland (646)
Massachusetts (4725)
Michigan (97)
Minnesota (217)
Mississippi (3)
Missouri (30)
Montana (14)
Nebraska (4)
Nevada (27)
New Hampshire (17)
New Jersey (1447)
New Mexico (12)
New York (1510)
North Carolina (732)
North Dakota (7)
Northern California (2799)
Ohio (157)
Oklahoma (11)
Oregon (22)
Pennsylvania (1104)
Puerto Rico (8)
Rhode Island (25)
South America (213)
South Carolina (6)
Southern California (2324)
Tennessee (33)
Texas (757)
United States (19867)
Utah (82)
Virginia (121)
Washington D.C. (36)
Washington State (504)
West Virginia (1)
Wisconsin (29)
278,251 Results for "crispr therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy Casgevy. While Vertex handles the market, CRISPR has been focused on its clinical program.
May 7, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
CRISPR Therapeutics to Participate in Upcoming September 2025 Investor Conferences
September 3, 2025
·
1 min read
Collaboration
CRISPR Expands Focus, Pays Up To $95M in Sirius’ siRNA Pact
The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.
May 20, 2025
·
2 min read
·
Tristan Manalac
Press Releases
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
September 23, 2025
·
9 min read
Press Releases
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025
September 10, 2025
·
5 min read
Press Releases
Flashpoint Therapeutics Announces Major Publication Supporting Application of its Proprietary Structural Nanomedicine Platform to CRISPR-based Therapeutics
September 4, 2025
·
3 min read
Gene editing
‘Safer’ CRISPR: Base Editing Breaks Through in the Clinic as Beam, Verve Advance
Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative to conventional CRISPR. Clinical results have so far been promising.
May 5, 2025
·
9 min read
·
Shawna Williams
Press Releases
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
October 10, 2025
·
6 min read
Press Releases
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 5, 2025
·
20 min read
Press Releases
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
September 10, 2025
·
5 min read
1 of 27,826
Next
